Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Plos One
|
May 6, 2010
Differential control of Notch1 gene transcription by Klf4 and Sp3 transcription factors in normal versus cancer-derived keratinocytes
Chiara Lambertini, Serafino Pantano, G Paolo Dotto
Journal of Clinical Pathology
|
November 6, 2012
Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system
Benedetta Belloni, Chiara Lambertini, Paolo Nuciforo, et al.
Regulatory Peptides
|
November 6, 2013
Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies
Chiara Lambertini, Patrizia Barzaghi-Rinaudo, Lisa D'Amato, et al.
Nature Cell Biology
|
July 8, 2008
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer
Vihren Kolev, Anna Mandinova, Juan Guinea-Viniegra, et al.
Neuroendocrinology
|
December 14, 2011
Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors
Herbert A Schmid, Chiara Lambertini, Harmke H van Vugt, et al.
Breast Cancer Research : BCR
|
January 11, 2023
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Sanne L de Haas, Dennis J Slamon, Miguel Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober, Carlos H Barrios, Naoki Niikura, et al.
Future Oncology (London, England)
|
November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
Sara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, et al.
The Lancet. Oncology
|
October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Plos One
|
May 6, 2010
Differential control of Notch1 gene transcription by Klf4 and Sp3 transcription factors in normal versus cancer-derived keratinocytes
Chiara Lambertini, Serafino Pantano, G Paolo Dotto
Journal of Clinical Pathology
|
November 6, 2012
Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system
Benedetta Belloni, Chiara Lambertini, Paolo Nuciforo, et al.
Regulatory Peptides
|
November 6, 2013
Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies
Chiara Lambertini, Patrizia Barzaghi-Rinaudo, Lisa D'Amato, et al.
Nature Cell Biology
|
July 8, 2008
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer
Vihren Kolev, Anna Mandinova, Juan Guinea-Viniegra, et al.
Neuroendocrinology
|
December 14, 2011
Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors
Herbert A Schmid, Chiara Lambertini, Harmke H van Vugt, et al.
Breast Cancer Research : BCR
|
January 11, 2023
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Sanne L de Haas, Dennis J Slamon, Miguel Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober, Carlos H Barrios, Naoki Niikura, et al.
Future Oncology (London, England)
|
November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
Sara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, et al.
The Lancet. Oncology
|
October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Page
of 2